How Does Jinxin Fertility Company Sell Its Products and Services?

Primary revenue comes from urban professional couples aged 32-42 with household incomes >800,000 RMB, who accounted for ~65% of China revenues in 2024; this cohort drives demand for IVF, genetic testing, and premium packages.

HRC Fertility targets single women and LGBTQ+ couples; this segment contributed >30% of U.S. revenue and grew ~15% year-over-year in 2025, supporting diversification of jinxin fertility sales and patient acquisition.

The group targets Southeast Asian and Middle Eastern medical tourists at flagship centers; related revenue rose ~25% year-over-year, driven by bundled service packages and medical tourism partnerships.

The 30-38 age group generates ~60% of all IVF cycles, so marketing, pricing, and service design prioritize this bracket for higher conversion and lifetime value.

Jinxin positions itself as premium and specialized, combining advanced lab capabilities, international affiliations, and concierge services to justify higher pricing and attract affluent clients seeking better success rates and convenience.

The promise of higher live-birth success rates, streamlined online appointment booking, telemedicine consultations, and tailored payment plans supports conversion; strategic B2B partnerships with hospitals and referral programs expand distribution for assisted reproductive technology.

Jinxin fertility sales rely on dedicated medical consultants who manage patient journeys in a direct, consultative model supported by online inquiry capture and telemedicine. The group sells treatments through clinic visits, partner hospital referrals, and international medical – tourism packages.

Standard IVF cycles are priced in China at roughly 40,000 to 100,000 RMB and often exceed 20,000 USD in U.S. operations; Third Generation IVF and PGT increase fees by about 50 to 100 percent, and financing or installment plans are offered to improve conversion.

Clinical success messaging is central: Jinxin emphasizes a 58-60 percent clinical pregnancy rate for patients under 35 to drive trust. Sales execution combines outcome transparency, one – to – one medical consultancy, targeted marketing, and a CRM that cut patient churn by 18 percent year – over – year.

Repeat revenue comes from multi – cycle treatment plans, PGT and third – generation upgrades, and ancillary services (egg freezing, genetic counseling). ARPU growth is driven by cross – sell of higher – margin tests and international patient packages.

Brand scale as China's largest IVF provider, expanded high-margin genetic screening services, and growing medical tourism channels drive demand; H2 2025 adjusted net profit rose 54.9 percent quarter-on-quarter, evidencing strengthening unit economics.

Omnichannel patient acquisition-direct clinic referrals, online appointment platforms, B2B hospital partnerships, and targeted international marketing-appears effective; patient volumes and pricing power support higher revenues despite promotional investments.

Key risks: regulatory shifts affecting IVF demand, competition compressing pricing, and dependency on ad efficiency for patient acquisition; near-term financials also reflect volatility from overseas goodwill impairments that hit FY 2025 net loss of 976 million RMB.

Outlook for 2025/2026 is strong-operationally but mixed financially: management's three-year shareholder return plan committing 50 to 80 percent of adjusted EBITDA to dividends and buybacks signals confidence in cash flow even as one-off charges create near-term volatility.